ProfileGDS5678 / 1422963_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 32% 29% 31% 30% 39% 38% 29% 31% 31% 32% 31% 31% 31% 31% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7598732
GSM967853U87-EV human glioblastoma xenograft - Control 22.6671829
GSM967854U87-EV human glioblastoma xenograft - Control 32.7105431
GSM967855U87-EV human glioblastoma xenograft - Control 42.6284130
GSM967856U87-EV human glioblastoma xenograft - Control 52.8432939
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9478938
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.707729
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6863131
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6765231
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7055932
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6938431
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6836531
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7007931
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6986631